|
|
Theravance, Inc. - Comparative Business Analysis Snapshot
Business Description
Theravance, Inc.. The Group's principal activity is that of a biopharmaceutical company with a pipeline of internally discovered product candidates. It focuses on the discovery, development and commercialization of small molecule medicines across a number of therapeutic areas including respiratory disease, bacterial infections and gastrointestinal motility dysfunction. Its programs include: telavancin for the treatment of serious Gram-positive bacterial infections with Astellas Pharma Inc. and Horizon program and the Bifunctional Muscarinic Antagonist-beta2 Agonist program with GlaxoSmithKline PLC.
Competitor Analysis
This analysis compares Theravance, Inc. with three other companies in closely related industry sectors.
The full Comparative Business Report is available to Subscribers or may be purchased individually. The full report generally includes the following sections:
- Sales Analysis: Recent Sales, Sales Growth, Sales per Employee
- Recent Stock Performance
- Company Valuation Ratios: Price/Earnings, Price/Book Value
- Price/Sales and 52 Week Price change
- Dividend Analysis
- Profitability Analysis: Gross Profit Margin, EBITDA Margin
- Earnings Before Extraordinary Items
- Inventory Analysis
- Research and Development Expenses
- Financial Position: Long Term Debt/Equity, Days Accounts Receivable, Days Inventory
- R&D Expenses/Sales
Not the Report you are looking for? Click here for more browsing options.
|
|
|
|
|
